glp-1 alzheimer's trial GLP-1R agonists protect against disease by rewiring energy regulation Disappointing GLP-1 Results in Alzheimer's

Date: October 18, 2015 Event: Annual Meeting of the Society for Neuroscience Location: Chicago Ee Rah Sung Timing of SCH 23390 Administration Influences Extinction of Conditioned Hyperactivity in Mice

Injury leads to the appearance of cells with characteristics of both microglia and astrocytes in mouse and human brain

(with the option for surgically placing pellets) treatments are more suitable for the optimal dose ranged from 0.1 mg/kg to 100 mg/kg over a time period of 4 to 8 weeks

Every treatment plan begins with a provider evaluation

Pocernich, and J

Always work under conditions appropriate for research-grade peptide handling